BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28887233)

  • 1. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
    Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
    Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.
    Suthandiram S; Gan GG; Zain SM; Bee PC; Lian LH; Chang KM; Ong TC; Mohamed Z
    Pharmacogenomics; 2014 Aug; 15(11):1479-94. PubMed ID: 25303299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
    Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
    Yousef AM; Farhad R; Alshamaseen D; Alsheikh A; Zawiah M; Kadi T
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):755-762. PubMed ID: 30684021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of variants in folate metabolism genes on 6-mercaptopurine induced toxicity during treatment for childhood acute lymphocytic leukemia.
    Milosevic G; Kotur N; Lazic J; Krstovski N; Stankovic B; Zukic B; Janic D; Jurisic V; Pavlovic S; Dokmanovic L
    J BUON; 2019; 24(5):2075-2083. PubMed ID: 31786878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
    Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
    Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival.
    Ongaro A; De Mattei M; Della Porta MG; Rigolin G; Ambrosio C; Di Raimondo F; Pellati A; Masieri FF; Caruso A; Catozzi L; Gemmati D
    Haematologica; 2009 Oct; 94(10):1391-8. PubMed ID: 19648163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.
    Erčulj N; Kotnik BF; Debeljak M; Jazbec J; Dolžan V
    Leuk Lymphoma; 2012 Jun; 53(6):1096-104. PubMed ID: 22074251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
    He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
    Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
    Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of RFC G80A polymorphism in Cretan children with acute lymphoblastic leukemia and its interaction with MTHFR C677T and A1298C polymorphisms.
    Karathanasis NV; Stiakaki E; Goulielmos GΝ; Kalmanti M
    Int J Lab Hematol; 2014 Aug; 36(4):425-30. PubMed ID: 24237708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate.
    D'Angelo V; Ramaglia M; Iannotta A; Francese M; Pota E; Affinita MC; Pecoraro G; Indolfi C; Di Martino M; Di Pinto D; Buffardi S; Poggi V; Indolfi P; Casale F
    Leuk Lymphoma; 2013 Dec; 54(12):2639-44. PubMed ID: 23488607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis.
    Yang L; Hu X; Xu L
    Tumour Biol; 2012 Oct; 33(5):1445-54. PubMed ID: 22528943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia.
    Kodidela S; Pradhan SC; Dubashi B; Basu D
    Eur J Clin Pharmacol; 2015 Nov; 71(11):1349-58. PubMed ID: 26335211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia.
    Eissa DS; Ahmed TM
    Blood Coagul Fibrinolysis; 2013 Mar; 24(2):181-8. PubMed ID: 23183238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
    Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate.
    Galbiatti AL; Castro R; Caldas HC; Padovani JA; Pavarino EC; Goloni-Bertollo EM
    Tumour Biol; 2013 Dec; 34(6):3765-71. PubMed ID: 23838799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.
    Chiusolo P; Giammarco S; Bellesi S; Metafuni E; Piccirillo N; De Ritis D; Marietti S; Federica S; Laurenti L; Fianchi L; Hohaus S; Giuseppe L; Sica S
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):691-6. PubMed ID: 21984221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.